Treats moderate acne vulgaris in females at least 15 years of age. ANDA 75808, held by Barr. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 75808 (Tri-Sprintec), held by Barr, was first approved by FDA on Dec 29, 2003, with 7 approved supplements and 0 published complete response letters.
Tri-Sprintec (norgestimate and ethinyl estradiol tablets) is a combination of norgestimate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. () Tri-Sprintec (norgestimate and ethinyl estradiol tablets) is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Tri-Sprintec (norgestimate and ethinyl estradiol tablets) should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. () 1.1 Oral Contraceptive
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 29, 2003 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tri-Sprintec0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Nov 27, 2023 | Supplement 45Labeling · Standard review | Approved | None posted |
| Nov 27, 2023 | Supplement 43Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 40Labeling · Standard review | Approved | None posted |
| Jan 27, 2022 | Supplement 34Labeling · Standard review | Approved | None posted |
| Apr 13, 2016 | Supplement 31Labeling · Standard review | Approved | None posted |
| Apr 13, 2016 | Supplement 30Labeling · Standard review | Approved | None posted |
| Feb 21, 2013 | Supplement 29Labeling · Standard review | Approved | None posted |
| Dec 29, 2003 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters